The Middle East & Africa molecular diagnostics market is expected to grow from USD 0.33 billion in 2026 to USD 0.47 billion by 2031, at a CAGR of 7.5%. This growth finds support from the high incidence of communicable diseases and the rising incidence of cancer. Moreover, government policies aimed at enhancing healthcare infrastructure, combined with growing awareness of early diagnosis, the adoption of cutting-edge diagnostic tools, and investments in healthcare services, collectively fuel steady growth in molecular diagnostics across the Middle East & Africa.
In September 2024, Roche (Switzerland) launched the cobas Respiratory flex test. The assay is the first diagnostic test to incorporate Roche’s proprietary TAGS (Temperature-activated Generation of Signal) technology, which combines multiplex polymerase chain reaction (PCR) with color, temperature control, and advanced data processing. The test enables the detection of up to 15 respiratory pathogens from a single PCR run.
To know about the assumptions considered for the study download the pdf brochure
In December 2024, the Federal Government of Nigeria entered into an agreement with Abbott Laboratories GmbH (Germany), Siemens Healthineers AG (Germany), and its Nigerian partner Tanit Medical Engineering. The agreement aims to enhance healthcare access and expand diagnostic capacity across Nigeria through improved medical and diagnostic infrastructure.
Companies such as QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Danaher (US), Hologic, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), BD (US), and Abbott (US) have adopted various strategies to expand their offerings and increase their market shares. These strategies include collaborations, acquisitions, development of new products, and contractual agreements, among other approaches.
With its strong presence in PCR-based diagnostics, Danaher (US) leads the Middle East & Africa molecular diagnostics (MDx) market. Additionally, the company has a well-established product portfolio of molecular testing platforms & assays. Automation, workflow efficiency, and scalable molecular solutions remain the focus of Danaher, which aligns well with the needs of end users in the Middle East & Africa. Besides this, its broad regional footprint and long-standing relationships with diagnostic providers support continued adoption of its MDx solutions across key markets.
F. Hoffmann-La Roche Ltd. (Switzerland) is one of the leading companies in the market due to its comprehensive & integrated product portfolio. The company offers end-to-end molecular solutions that combine testing platforms, automation, and a broad menu of assays across key clinical areas, enabling standardized and efficient testing. Roche’s strong focus on quality, reliability, and scalable workflows has supported the widespread adoption of its molecular systems in the region.
Market Ranking
Thermo Fisher Scientific (US), bioMérieux (France), Illumina (US), Danaher (US), and Roche (Switzerland) are some of the prominent players in this market, primarily owing to their diverse diagnostic portfolios and continuous technological developments.
Danaher is well established in PCR-based molecular diagnostics, supported by a broad range of assays and automated systems that generate consistent demand for consumables. Roche maintains a strong position through its integrated MDx portfolio, combining testing platforms, automation, and companion diagnostics. Illumina plays a central role in next-generation sequencing, with its platforms commonly used for cancer profiling, genetic testing, and advanced molecular analysis. bioMérieux is recognized for its focus on infectious disease diagnostics, providing solutions used for rapid & specific pathogen detection. Thermo Fisher Scientific contributes through its comprehensive molecular diagnostic offerings, including PCR and NGS platforms, reagents, and sample preparation solutions, which support a wide range of molecular diagnostic applications.
Related Reports:
Middle East & Africa Molecular Diagnostics Market by Product & Service (Kits, Instruments), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS), Application [Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)] - Forecast to 2031
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE